These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 16253392

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 3. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 4. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 5. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 6. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
    Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.
    Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
    [Abstract] [Full Text] [Related]

  • 7. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 8. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [Abstract] [Full Text] [Related]

  • 9. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [Abstract] [Full Text] [Related]

  • 11. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P, Lévesque M, Morissette M, Calon F, Dridi M, Di Paolo T, Parent A.
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [Abstract] [Full Text] [Related]

  • 12. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 13. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G, Morissette M, Parent M, Di Paolo T.
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [Abstract] [Full Text] [Related]

  • 14. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 15. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A, Ekesbo A, Grégoire L, Bangassoro E, Svensson KA, Tedroff J, Bédard PJ.
    Eur J Pharmacol; 2001 Feb 02; 412(3):247-54. PubMed ID: 11166288
    [Abstract] [Full Text] [Related]

  • 16. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Mar 02; 66():355-64. PubMed ID: 22884464
    [Abstract] [Full Text] [Related]

  • 17. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 18. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 28; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 19. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov 28; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 20. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.